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To the editor
Kawasaki disease (KD) is an acute self-limiting inﬂammatory
disorder, associated with systemic vasculitis. It is the leading cause
of childhood-acquired heart disease in the developed world.1,2
The most important complication of KD is coronary artery
vasculitis. Without treatment, this causes coronary artery aneur-
ysms (CAA) in 15–25% of KD patients, while a further 2–3%
develop myocardial infarction, ischemic heart disease, or sudden
death.1 Treatment with intravenous immunoglobulin (IVIG) plus
aspirin can resolve inﬂammation and reduce the occurrence of
CAA.1,2 However, in about 20% of cases IVIG fails to resolve the
inﬂammation, leading to persistent vasculitis: these patients have
increased risk of developing CAA unless they receive additional
treatment.1,2 Recently, IVIG plus adjuvant glucocorticoid hormones
(GCs) has been shown to be an effective therapy for these
patients,3,4 suggesting that GCs may complement IVIG treatment
in severe KD. However, this remains controversial with others
reporting that additional GCs did not improve coronary artery
outcomes and may even cause CAA due to impaired vascular
remodeling.5,6 An insight into how endogenous glucocorticoids
might contribute to disease resolution could be useful for
consideration of glucocorticoid therapy. Here we hypothesized
that failure to appropriately regulate endogenous GC signaling in
inﬂammatory cells may contribute to persistent inﬂammation in
KD. Intracellular GC levels in peripheral tissues are controlled by
pre-receptor metabolism by 11β-hydroxysteroid dehydrogenase
(11β-HSD). 11β-HSD1 converts intrinsically inert cortisone to active
cortisol, increasing intracellular GC levels available to activate
glucocorticoid receptor (GR).7 We have previously shown that the
direction of regulation of 11β-HSD1 by dexamethasone in
peripheral blood mononuclear cells (PBMC) is associated with
the cytotoxic effects of GCs in acute lymphoblastic leukemia, with
upregulation in glucocorticoid-sensitive cells but downregulation
or no change in patient cells that are resistant to the pro-apoptotic
effects of GC.8 Therefore, the aim of this study was to establish
whether 11β-HSD1 in PBMC is associated with acute inﬂammation
in KD.
Levels of 11β-HSD1 and GR mRNA were measured in PBMC
isolated from all children diagnosed with KD at Teine-Keijinkai
Hospital, Sapporo, Japan between April 2015 and January 2018 (a
total of 31). Diagnosis of KD was made by pediatricians on the
basis of clinical and laboratory ﬁndings according to clinical
guideline.1 IVIG treatment (2 g/kg over 24 h) was initiated in all
patients on day 5 or 6 after the onset of high fever (>38 °C). IVIG
sensitivity/resistance was determined from the initial response to
IVIG treatment according to resolution of fever (<38 °C). Nineteen
patients were classiﬁed as IVIG-sensitive patients, who showed
complete resolution of high fever within 48 h after commencing
IVIG treatment and remained afebrile. Twelve patients were
classiﬁed as IVIG-resistant due to persistent fever >38 °C following
IVIG treatment. There was no signiﬁcant difference in age or
gender between patients who responded to IVIG (IVIG-sensitive)
and those who were unresponsive (IVIG-resistant) (Table 1).
Adjuvant GC therapy was not used in this study, but additional
IVIG treatment (2 g/kg) was administered for patients with high
fever >38 °C for >60 h after commencement of the initial IVIG
treatment. None of the patients developed CAA. Peripheral blood
samples (3 ml) were obtained before (day 4 after the onset of high
fever) and after IVIG treatment (day 8) with informed consent.
Sampling was also carried out on day 10 for representative
patients (Case 1 and Case 2). PBMC isolation, RNA extraction, and
quantitative reverse transcriptase–polymerase chain reaction
(qRT-PCR) were performed as previously described.8,9 Values for
RNA are mean ± S.E.M. and were analyzed using a paired Student’s
t test (two-tailed). GAPDH served as internal control. Patient
characteristics and laboratory data were compared using
Mann–Whitney U test for age, body temperature, white blood
cell (WBC) counts, and C-reactive protein (CRP) and chi-squared
test for gender. Signiﬁcance was set at p < 0.05.
The clinical courses for patients representative of IVIG-sensitive
(Case 1) and IVIG-resistant (Case 2) patients are shown in Fig. 1a, c,
respectively. In Case 1, an 8-month-old boy was diagnosed as
having KD because of 5 days of fever and other clinical symptoms.
Inﬂammatory markers (WBC and CRP) were elevated at diagnosis
(Fig. 1a) and treatment with 2 g/kg IVIG and aspirin was initiated.
The following day, the fever had resolved and inﬂammatory
markers were decreased (Fig. 1a). In Case 2, a 3-year-old boy was
diagnosed with KD on day 5 of high fever (>38 °C). Two g/kg IVIG
and aspirin were administered but were ineffective, nor was there
a response to additional IVIG treatment given on day 7 (Fig. 1c).
On day 9 after onset of high fever, therapeutic plasma exchange
(TPE) was carried out in Intensive Care Unit for 3 consecutive days.
Following TPE, resolution of fever was achieved and other
symptoms of KD gradually resolved (Fig. 1c). Neither boy
developed CAA. To investigate whether HSD11B1 (encoding 11β-
HSD1) mRNA in PBMC was associated with resolution of
inﬂammation, qRT-PCR was used to measure the levels. The
expression of HSD11B1 mRNA in PBMC increased over two-fold
following IVIG treatment in Case 1, with a four-fold increase at
resolution of inﬂammation and discharge of the patient (Fig. 1b).
In contrast, levels of HSD11B1 mRNA in Case 2 were unchanged by
IVIG treatment and showed only a modest increase (two-fold)
following commencement of TPE (Fig. 1d).
These case studies suggested an association between HSD11B1
mRNA levels in PBMC and resolution of inﬂammation in KD.
Accordingly, we measured the markers of glucocorticoid sensitiv-
ity, HSD11B1 and NR3C1 (nuclear receptor subfamily 3 group C
member 1), encoding GR mRNA levels in PBMC isolated from all
patients prior to IVIG treatment (day 4) and following IVIG
treatment (day 8). Patient characteristics are shown in Table 1.
Following IVIG treatment, body temperature and WBC were
signiﬁcantly lower in IVIG-sensitive than in IVIG-resistant group.
None of the patients developed CAA. There was no signiﬁcant
difference in the basal levels of HSD11B1 and NR3C1 mRNA
between IVIG-sensitive and IVIG-resistant KD (Table 1). However,
following IVIG treatment, HSD11B1 mRNA levels were signiﬁcantly
increased in IVIG-sensitive KD but not in IVIG-resistant KD (Table 1).
There was no signiﬁcant effect of IVIG treatment on NR3C1 mRNA
levels in either group (Table 1). Thus increased expression of
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Table 1. Summary of Kawasaki disease patient characteristics
N= 31 IVIG-sensitive (n= 19) IVIG-resistant (n= 12) p (sensitive vs. resistant)
Age (years), mean (range) 2.89 (0.7–6.1) 3.07 (1.3–5.2) 0.715
Gender (%) Boys 53% 50%
Girls 47% 50%
Body temperature (°C), mean ± S.E.M.
Before IVIG 39.57 ± 0.13 39.68 ± 0.21 0.7141
After IVIG 36.78 ± 0.08 38.86 ± 0.25 <0.0001
Laboratory data, mean ± S.E.M.
WBC (per mm3) Before IVIG 12986 ± 820 15073 ± 1124 0.0777
After IVIG 6415 ± 570 10324 ± 1138 0.0057
CRP (mg/dl) Before IVIG 8.71 ± 1.27 9.72 ± 1.55 0.5034
After IVIG 2.56 ± 0.63 5.03 ± 1.70 0.2068
mRNA levels, mean ± S.E.M.
HSD11B1 mRNA Before IVIG 1.849 ± 0.392 1.749 ± 0.765 0.5039
After IVIG 4.330 ± 1.146* 1.361 ± 0.237 0.3307
NR3C1 mRNA Before IVIG 5.679 ± 0.870 3.860 ± 0.497 0.1246
After IVIG 7.423 ± 1.847 4.336 ± 0.613 0.4548
CRP C-reactive protein, IVIG intravenous immunoglobulin, WBC white blood cell
*p= 0.0386
Bold values indicate statistical signiﬁcance at p < 0.05
41
IVIG
a c
db
IVIG IVIG
TPE
Case 1
IVIG-sensitive KD IVIG-resistant KD
Case 2
IVIG-resistant KD
Case 2
IVIG-sensitive KD
Case 1
40
39
38
Bo
dy
 te
m
pe
ra
tu
re
 (°
C)
Bo
dy
 te
m
pe
ra
tu
re
 (°
C)
37
36
5
0
2
4
6
8
10
H
SD
11
B1
 
m
R
N
A
H
SD
11
B1
 
m
R
N
A
0
2
4
6
8
10
6
Day 4
11,130WBC 5520 7120
6.41CRP 2.92 0.93 (mg/dl)
(cells/mm3) 14,860WBC 12,430 15,830
8.04CRP 5.80 5.21 (mg/dl)
(cells/mm3)
Day 8 Day 10
Day 4 Day 8 Day 10 Day 4 Day 8 Day 10
Day 4 Day 8 Day 10
7 8 9 10 11
Discharged
Days of illness Days of illness
12 13 14 15 5 6 7 8 9 10 11 12 13 14 15
41
42
40
39
38
37
36
Fig. 1 Clinical courses and peripheral glucocorticoid hormone signaling in representative patients. a, b Body temperature, white blood cell
(WBC), C-reactive protein (CRP), and HSD11B1 mRNA levels in intravenous immunoglobulin (IVIG)-sensitive Case 1. c, d Body temperature,
WBC, CRP, and HSD11B1 mRNA levels in IVIG-resistant Case 2. HSD11B1 mRNA levels were measured relative to GAPDH mRNA levels and are
expressed in arbitrary units
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HSD11B1 in PBMC following IVIG treatment is associated with
resolution of inﬂammation following IVIG treatment in KD. This
could reﬂect induction of HSD11B1 in a stable population of
circulating PBMC or may reﬂect a gradual change in the
population of PBMC themselves as the inﬂammation resolves
with disappearance of lower HSD11B1-expressing cells from
the circulation and replacement with a higher expressing cell
population. Different immune cell populations express HSD11B1 at
different levels and it varies with immune cell activation state.7,10
Pro-inﬂammatory cytokines can induce HSD11B1,7 which may
differ between IVIG-sensitive and IVIG-resistant KD. It is also
possible that fever itself affected HSD11B1 mRNA levels. It is
intriguing to speculate that genetic variation in the HSD11B1 gene
could contribute to the differential responses of KD patients.
The signiﬁcance of increased PBMC HSD11B1 expression for KD
is currently unclear. However, it will be important to establish
whether this association between an increase in the levels of
HSD11B1 expression in PBMC and the resolution of inﬂammation
is generalizable to other acute and life-threatening inﬂammatory
disorders, including sepsis. It is interesting to speculate that an
increase in the HSD11B1 expression in PBMC may be a mechanism
to promote and assist the resolution of inﬂammation. Increased
11β-HSD1 activity in PBMC is predicted to increase the
intracellular levels of cortisol generated from cortisone, thereby
amplifying intracellular GC-mediated attenuation of proinﬂamma-
tory cytokine action in PBMC of IVIG-sensitive KD. The failure to
upregulate HSD11B1 in PBMC in IVIG-resistant KD patients might
contribute to the persistence of inﬂammation in these patients. If
this is the case for IVIG-resistant patients, then additional GC
therapy might be of therapeutic beneﬁt to restore GC action as
has been suggested.3 However, an early report showed a high
incidence of CAA in patients who received a prolonged course of
oral prednisolone.11 Further trials are urgently needed to establish
whether IVIG-resistant patients can be safely treated by GCs
without occurrence of CAA. Understanding the role of endogen-
ous glucocorticoid signaling in immune cells during the course of
KD may highlight future possible therapeutic avenues to treat
IVIG-resistant KD. We evaluated only Japanese patients in a single
center, who may not be representative of KD in other ethnic
groups. However, our ﬁndings may reﬂect the course of acute
inﬂammation and its resolution and could be useful to understand
other acute inﬂammatory conditions as well as the response to
IVIG therapy in KD.
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